Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 12/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4707838 | 0.86 | NQO1 (0.47) | APPCA1CA2CA9NQO1 | |
| SCHEMBL5540965 | 0.80 | APP (0.52) | APP | |
| SCHEMBL6469917 | 0.78 | APP (0.50) | APP | |
| SCHEMBL11867619 | 0.78 | APP (0.61) | APPRXRARXRBCA1CA2 | |
| SCHEMBL7533336 | 0.76 | APP (0.58) | APPRXRARXRBCA1CA2 | |
| SCHEMBL10566226 | 0.75 | L3MBTL1 (0.38) | CA1CA2CA9NQO1 | |
| SCHEMBL6750348 | 0.75 | APP (0.47) | APP | |
| SCHEMBL24016966 | 0.74 | APP (0.56) | APPRXRARXRBCA1CA2 | |
| SCHEMBL7470630 | 0.74 | TDP1 (0.58) | APP | |
| SCHEMBL1224848 | 0.74 | APP (0.47) | APPRXRARXRBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024466-A | Tetra-substituted olefin compound and use thereof | 卫材 R&D 管理有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-107847498-B | Tetra-substituted olefin compound and use thereof | 卫材R&D管理有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| EP-2061789-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008032858-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | APP 3353/4885RXRA 351/4885RXRB 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.